Bill Roth provides his thoughts on top trends impacting pharma's top executives.
In an interview with Nicholas Saraceno, Bill Roth, SVP, Managing Partner, Blue Fin Group, discusses top trends impacting executives in 2023 and what it will lead into for 2024.
Roth: I think what people are realizing is that they can't run their commercial strategies and silos anymore. They can't allow marketing to do their thing. It's the alignment of those functions that matter so much. That is actually harder than you'd think.
The base function of what I think our everyday roles are is that we align the groups. We help marketing understand what access means and vice versa. From there, they are trying to get their heads around PBMs, removal of the AmCap, the IRA, how you balance all of the discounts and fees, and try to drive utilization. There is no recipe that's out there.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.